Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
Bullboard Posts
User Avatar Image
(0)
•••
Post by freedom2020on Oct 20, 2015 7:53pm
255 Views
Post# 24210852

Bio-tech corrections provide opportunities

Bio-tech corrections provide opportunitiesArticle on CTV with comments by Mr. O'leary
Kevin on CTV:
The businessman said in recent days he's "doubled downed" on the biotech sector, after a tweet from democratic presidential candidate Hillary Clinton about price gouging in pharmaceuticals sent biotech stocks tumbling.
Hillary Clinton on twitter:
Price gouging like this in the specialty drug market is outrageous.
Tomorrow I'll lay out a plan to take it on.
Kevin on CTV:
"There's nothing better than having a politician make promises you know they can't keep and correcting whole sectors," he said. "Even if she becomes president, she'll never be able to implement pricing into drug manufacturing."

Source:
https://www.ctvnews.ca/5things/how-to-invest-like-kevin-o-leary-1.2616267
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities